5 hours ago
Image caption More than 10,000 people in the UK suffer from cystic fibrosis, which causes fatal lung damageA pharmaceutical company has been urged to drop the price of a life-changing cystic fibrosis drug for the NHS. Orkambi, which is made by Vertex Pharmaceuticals, is not available on the NHS and health ministers have called for an "urgent resolution". NHS England made a counter-offer to the initial deal but Vertex said that would not allow them to fund future medicines. Vertex said it wanted to reach an agreement "as soon as possible". Cystic fibrosis is a life-shortening genetic condition that causes fatal lung damage and affects around 10,400 people in the UK. Only around half of those with cystic fibrosis live to celebrate their 40th birthday. Orkambi is for people with the F508del mutation, which causes the production of an abnormal protein that disrupts how water and chloride are transported in the body. The drug has been shown in clinical trials to improve lung function..